Skip to main navigation Skip to search Skip to main content

US FDA approves Janssen Pharma's Carvykti to treat relapsed or refractory multiple myeloma

Press/Media

Period2 Mar 2022

Media coverage

1

Media coverage

  • TitleUS FDA approves Janssen Pharma's Carvykti to treat relapsed or refractory multiple myeloma
    Media name/outletPharmaBiz
    Country/TerritoryIndia
    Date2/03/22
    PersonsSundar Jagannath
View all 1
View less